HCA Healthcare, Inc. (NYSE:HCA – Get Rating) – Stock analysts at Oppenheimer dropped their Q2 2022 earnings per share estimates for shares of HCA Healthcare in a research note issued on Friday, June 17th. Oppenheimer analyst M. Wiederhorn now forecasts that the company will earn $3.69 per share for the quarter, down from their previous estimate of $3.99. The consensus estimate for HCA Healthcare’s current full-year earnings is $17.12 per share. Oppenheimer also issued estimates for HCA Healthcare’s FY2022 earnings at $16.69 EPS, Q1 2023 earnings at $4.50 EPS, Q3 2023 earnings at $4.69 EPS and Q4 2023 earnings at $5.10 EPS.
HCA Healthcare (NYSE:HCA – Get Rating) last released its quarterly earnings results on Friday, April 22nd. The company reported $4.12 earnings per share for the quarter, missing the consensus estimate of $4.27 by ($0.15). The firm had revenue of $14.95 billion for the quarter, compared to the consensus estimate of $14.72 billion. HCA Healthcare had a net margin of 11.40% and a return on equity of 405.72%. HCA Healthcare’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same period in the previous year, the company earned $4.14 earnings per share.
Other equities research analysts have also issued reports about the company. UBS Group reduced their price objective on HCA Healthcare from $289.00 to $241.00 and set a “buy” rating for the company in a research note on Tuesday, April 26th. Credit Suisse Group reduced their price objective on HCA Healthcare from $296.00 to $260.00 and set an “outperform” rating for the company in a research note on Monday, April 25th. Cowen cut their price target on HCA Healthcare from $265.00 to $241.00 in a research note on Monday, April 25th. Jefferies Financial Group cut their price target on HCA Healthcare from $310.00 to $275.00 in a research note on Monday, April 25th. Finally, Mizuho cut their price target on HCA Healthcare from $290.00 to $260.00 in a research note on Tuesday, May 3rd. Five equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $259.77.
NYSE HCA opened at $173.10 on Monday. The company has a debt-to-equity ratio of 87.46, a current ratio of 1.43 and a quick ratio of 1.24. The stock has a market capitalization of $51.15 billion, a price-to-earnings ratio of 8.15, a PEG ratio of 1.10 and a beta of 1.61. HCA Healthcare has a 1-year low of $169.13 and a 1-year high of $279.02. The business’s fifty day moving average price is $217.66 and its 200-day moving average price is $238.94.
A number of hedge funds and other institutional investors have recently bought and sold shares of HCA. Equitec Proprietary Markets LLC acquired a new position in HCA Healthcare during the fourth quarter valued at $26,000. Baltimore Washington Financial Advisors Inc. acquired a new position in shares of HCA Healthcare in the fourth quarter worth about $26,000. GoalVest Advisory LLC acquired a new position in shares of HCA Healthcare in the first quarter worth about $26,000. Amplius Wealth Advisors LLC acquired a new position in shares of HCA Healthcare in the fourth quarter worth about $27,000. Finally, Wolff Wiese Magana LLC increased its stake in shares of HCA Healthcare by 1,833.3% during the first quarter. Wolff Wiese Magana LLC now owns 116 shares of the company’s stock worth $29,000 after purchasing an additional 110 shares in the last quarter. Institutional investors own 67.87% of the company’s stock.
In other news, SVP Jennifer Berres sold 2,358 shares of HCA Healthcare stock in a transaction on Friday, May 13th. The shares were sold at an average price of $218.87, for a total transaction of $516,095.46. Following the completion of the sale, the senior vice president now directly owns 11,392 shares in the company, valued at $2,493,367.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Andrea B. Smith acquired 1,160 shares of the stock in a transaction dated Thursday, April 28th. The shares were bought at an average price of $213.63 per share, with a total value of $247,810.80. Following the completion of the purchase, the director now directly owns 2,239 shares of the company’s stock, valued at approximately $478,317.57. The disclosure for this purchase can be found here. Insiders acquired 91,370 shares of company stock worth $19,373,375 over the last ninety days. Corporate insiders own 1.50% of the company’s stock.
The company also recently declared a quarterly dividend, which will be paid on Thursday, June 30th. Shareholders of record on Thursday, June 16th will be issued a $0.56 dividend. This represents a $2.24 annualized dividend and a yield of 1.29%. The ex-dividend date of this dividend is Wednesday, June 15th. HCA Healthcare’s dividend payout ratio is currently 10.54%.
HCA Healthcare Company Profile (Get Rating)
HCA Healthcare, Inc, through its subsidiaries, provides health care services company in the United States. The company operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.
Receive News & Ratings for HCA Healthcare Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for HCA Healthcare and related companies with MarketBeat.com’s FREE daily email newsletter.